Daniel Cressy spent his childhood looking up at commercial airplanes, dreaming of the day he would sit in the cockpit. But the Federal Aviation Administration had a blunt answer for the Metairie, Louisiana native: your diagnosis makes licensing impossible.
Cressy had sickle cell disease, an inherited blood disorder that warps round red blood cells into rigid, crescent shapes. At high altitudes, the risks of severe pain, sudden strokes, and organ damage multiply. The FAA told him he could only fly if he somehow cured a disease known for being lifelong and brutal. Discover more on a similar subject: this related article.
On June 22, 2026, the 23-year-old stood inside Manning Family Children's Hospital in New Orleans and rang a ceremonial bell. He had just become the first person in Louisiana and the broader Gulf South region to be functionally cured of sickle cell disease using Casgevy, the world's first approved CRISPR-based gene therapy.
This isn't just a feel-good local interest story about an aspiring pilot. It is a massive real-world test for genetic medicine. Louisiana has the highest per capita rate of sickle cell disease in the United States, affecting roughly 3,000 residents statewide, while the broader US population sits at about 100,000. For decades, the medical establishment largely ignored or undertreated this population. Now, a sci-fi level cure is sitting on the table, but it comes with immense physical toll and a staggering price tag that exposes the deep cracks in our healthcare infrastructure. Additional reporting by Medical News Today highlights similar perspectives on the subject.
How the CRISPR Trick Actually Works
Most people assume gene editing works like digital white-out, where scientists go into your DNA, snip out the bad mutation, and paste in a correct sequence. That is not what happens with Casgevy.
The treatment targets a biological backup system we all carry but turn off in infancy. When you are in the womb, your body produces fetal hemoglobin, a protein that binds oxygen exceptionally well and doesn't sickle. Shortly after birth, a genetic switch called BCL11A flips on, telling your body to stop making fetal hemoglobin and start making adult hemoglobin. If you inherited the sickle cell mutation, that adult hemoglobin is defective.
Scientists use CRISPR-Cas9 technology to target the BCL11A gene itself. Instead of fixing the mutated adult hemoglobin gene, they break the switch that turned off the healthy fetal hemoglobin.
The physical process is long and grueling. For Cressy, the journey took more than two years from preparation to recovery.
- Cell Harvesting: Doctors collected blood-forming stem cells from Cressy's body in late 2025.
- The Journey to Scotland: Because the manufacturing infrastructure is incredibly specialized, his frozen cells were shipped across the Atlantic to a lab in Scotland for the actual CRISPR editing.
- The Blank Slate: The edited cells returned to New Orleans in March 2026. Before they could be reinfused, Cressy had to undergo aggressive high-dose chemotherapy. This step destroys the existing bone marrow to clear space for the new cells. It also causes severe nausea, hair loss, and temporary infertility risks.
- The Reset: On March 18, 2026, the modified cells were infused back into his bloodstream. They migrated to his wiped-out bone marrow, attached, and began pumping out massive quantities of fetal hemoglobin.
Three months after the infusion, doctors confirmed Cressy's hemoglobin levels were the highest of his life, with no active sickle cells remaining in his system. His body is permanently tricked into producing infant-style blood that simply cannot deform or block his blood vessels.
The Brutal Reality of the Multi-Million Dollar Price Tag
The science is an undeniable triumph, but the economics are terrifying. Vertex Pharmaceuticals lists Casgevy at a jaw-dropping $2.2 million per patient. A competing gene-addition therapy, Lyfgenia, costs $3.1 million.
Sickle cell disease is passed down predominantly among people of African ancestry. Because of systemic economic disparities, the exact population that carries the heaviest burden of this disease is the least equipped to pay a multi-million dollar medical bill.
Cressy managed to access his cure because he was covered under Louisiana's Medicaid program. In late 2025, Louisiana became one of 33 states to participate in a federal model designed to standardize and expand Medicaid access for gene therapies. But that leaves 17 states where a low-income patient has virtually zero path to receiving this treatment.
Even if insurance covers the drug cost, the hidden expenses can break a family. The treatment requires weeks of inpatient hospitalization, months of regular outpatient monitoring, and time off work for both the patient and their caregivers. If you live hours away from an authorized specialty center like Manning Family Children's Hospital, the cost of lodging, travel, and childcare makes the cure practically unreachable.
Beyond the Lab
Cressy is calling his post-cure reality "Life 2." He is already working toward obtaining his first-class medical certificate from the FAA so he can finally begin commercial flight training.
But he isn't just focusing on his own career. He has started a nonprofit organization called the Privileged Pilots Project and is writing a book titled Blessing in the Skies. His goal is to help other sickle cell patients navigate the isolating, confusing path toward treatment. He noted during his release that a person's ability to access a cure shouldn't be defined by their zip code.
For healthcare providers and state Medicaid directors, the next step is figuring out how to scale this breakthrough. We have a definitive cure for an agonizing disease that has devastated families for generations. The bottleneck is no longer the science in the lab. It is the funding, the manufacturing logistics, and the political will to make a $2.2 million infusion accessible to the thousands of people still waiting on the ground.
